In triple-negative breast cancer (TNBC), FAK mRNA expression is correlated with expression of the PD-1 ligand, PD-L1, and FAK inhibition improved response to PD-L1-neutralizing antibodies [17,46]. The gene discussed is PTK2; the disease is triple-negative breast carcinoma.